Europe/India/Near East USA Asia
Bachem AG Bachem Americas, Inc. Bachem Japan K.K.
Hauptstrasse 144 3132 Kashiwa Street Ueno Bldg, 8F
4416 Bubendorf - Switzerland Torrance, CA 90505 - USA 1-9-10 Nihonbashi-Horidome cho, Chuo-ku
Tel +41 58 595 2021 Tel +1 888 422 2436 Tokyo 103-0012 - Japan
Fax +41 58 595 2040 Tel +1 888 4BACHEM Tel +81 3 6661 0774
Email Fax +1 310 539 9428 Email


Press Releases
23. Aug 2019

Half-Year Report 2019: Record sales of 134.5 million CHF and surge in operating income in the first half

Significant sales and EBIT growth EBITDA at 27.1% and EBIT at 18.2% of sales Capital increase...

08. May 2019

Results of the capital increase

Only available in the German version Please click here 

23. Apr 2019

Key figures for capital increase as announced

Only available in the german version Please click here

10. Apr 2019

Annual General Meeting approves all Board proposals

Only available in the german version Please click here

08. Mar 2019

2018 fiscal year: Record sales and increased operating income

Continued growth and record sales of 282.5 million CHFIncrease in EBIT margin to 19.4% and...

08. Mar 2019

Bachem plans capital increase

Only available on the german version Please click here

26. Oct 2018

Thomas Meier to become new COO of Bachem Group

Bubendorf/Basel, Switzerland, October 26, 2018 – Bachem (SIX: BANB) announced today that Thomas...

24. Aug 2018

First half of 2018: Further rise in net profit; delayed sales/EBIT to be made good in second half

Net income 14.9% of sales EBITDA at 26.0% and EBIT at 16.2% of sales Delayed sales and EBIT...

20. Jul 2018

Bachem: Footprint in Asia

Bubendorf/Basel, July 20, 2018 – Bachem (SIX: BANB) announced today the establishment of a new...

04. May 2018

Bachem site in St Helens, UK, obtains ISO certification

Bubendorf/Basel, May 4, 2018 – Bachem (SIX: BANB) announced today that the UK site has been...

16. Mar 2018

Fiscal year 2017: Continued increase in sales, profitability and earnings

Continued growth and new record sales of 261.6 million CHFEBIT margin rises to 19.3% while EBITDA...

01. Sep 2017

Dr. Anne-Kathrin Stoller to assume CMO position at Bachem

Bubendorf/Basel, September 1, 2017 – Bachem (SIX: BANB) announced today that Dr. Anne-Kathrin...

25. Aug 2017

First half of 2017: New record sales and a solid operating result

Sales and EBIT further increasedEBITDA at 26.6% and EBIT at 17.9% of salesNet profit affected by...

17. Mar 2017

Fiscal year 2016: Another year of strong sales and profit growth

Momentum intact and new sales record setEBIT margin climbs to 19.1%, EBITDA margin to...

24. Feb 2017

Bachem expands its Corporate Executive Committee

Bubendorf/Basel, February 24, 2017 – Bachem (SIX: BANB) announced today that Dr. Alex Fässler has...

07. Feb 2017

Bachem renews supply contract with AstraZeneca

Bubendorf/Basel, 7 February 2017 – The Bachem Group (SIX: BANB) announced today the renewal of its...

04. Oct 2016

Bachem – Reinforced Collaboration with DOTTIKON ES on Novel Amino Acids

Bubendorf/Basel, Switzerland, October 4, 2016 – Bachem Group (SIX: BANB) and DOTTIKON ES announce...

26. Aug 2016

First half of 2016: New sales record and sharp jump in profits

New sales record with 13.9% year-on-year growth EBITDA at 26.2% and EBIT at 18.3% of salesNet income...

11. Mar 2016

Fiscal year 2015: Record sales and creation of new jobs

· Sales grow 13.8% in local currency and pass the 200 million CHF thresholdEBIT margin of 18.5% and...

07. Sep 2015

Bachem and ILS extend their collaboration in Japan by an Exclusive Agency Agreement

Bubendorf/Basel, Switzerland and Ibaraki, Japan, September 7th, 2015 – Bachem (SIX: BANB) and ILS...

28. Aug 2015

First half 2015: Record sales and solid profit growth

Bubendorf/Basel, August 28, 2015 – Bachem Group (SIX: BANB) increased its sales by about 15% to...

17. Apr 2015

Bachem engages Professor Stephen B.H. Kent as Scientific Advisor and enters collaboration with the University of Chicago

Bubendorf/Basel, April 17, 2015 - Bachem (SIX: BANB) is pleased to announce today that it has...

20. Mar 2015

Fiscal year 2014: Renewed sales growth and sharply higher profits

Bubendorf/Basel, March 20, 2015 – Bachem Group (SIX: BANB), the technology leader in the field of...

27. Feb 2015

Bachem acquires American Peptide Company

Bubendorf/Basel, February 27, 2015 – Bachem (SIX: BANB), the leading peptide manufacturer, announced...

06. Oct 2014

Bachem AG and GlyTech, Inc. announce co-promotion agreement

Bubendorf/Basel, October 7, 2014 - Bachem the leading peptide manufacturer, and GlyTech Inc. (Kyoto,...

29. Aug 2014

First half 2014: Strong sales and profit growth / guidance confirmed

Bubendorf/Basel, August 29, 2014 – Bachem Group (SIX: BANB) significantly improved its performance...

25. Aug 2014

Dr. Guenther Loidl to assume CTO position at Bachem Group

Bubendorf/Basel, August 25, 2014 – Bachem (SIX: BANB) announced today that Dr. Günther Loidl will...

21. Mar 2014

Fiscal Year 2013: Sales beat overall market growth, profits sharply higher

Bachem Group (SIX: BANB), the market leader in the field of peptide chemistry with a distinctive...

28. Nov 2013

Prof. Dr. Helma Wennemers nominated for election to Board of Directors and early cancellation of the temporary increase in weekly working hours

Bubendorf/Basel, November 28, 2013 – At its latest meeting the Board of Directors of Bachem Holding...

23. Aug 2013

Half-Year Report 2013: Confirmation of upward trend

Bubendorf/Basel, August 23, 2013 – Bachem Group (SIX: BANB) continued to grow in the first half of...

10. Jul 2013

Pioneering breakthrough in the chemical synthesis of Interferon β-1a

Bubendorf/Basel, Switzerland and Kyoto, Japan July 10, 2013 - GlyTech, Inc. (Kyoto, Japan) and...

25. Apr 2013

Bachem switching from IFRS to Swiss GAAP FER

Bubendorf/Basel, April 25, 2013 – The Board of Directors of Bachem Holding AG (SIX: BANB) passed a...

15. Mar 2013

2012 financial year: Bachem clearly tops prior-year results at all levels

Bachem Group (SIX: BANB) generated sales of 157.3 million CHF in the 2012 financial year in the face...

24. Aug 2012

Bachem well on track in a challenging market

Bachem Group (SIX: BANB) reported sales of 76.2 million CHF for the first half of 2012. Sales were...

16. Mar 2012

Bachem confirms upward trend in its anniversary year - positive developments in terms of local sales, productivity and cost management

Bachem Group (SIX: BANB) recorded sales of 145.8 million CHF in the challenging 2011 financial year...

07. Mar 2012

Dr. José de Chastonay appointed Chief Marketing Officer of the Bachem Group

Bachem (SIX: BANB) announced today that Dr. José de Chastonay will succeed Dr. Lester Mills as Chief...

02. Mar 2012

Bachem and BioSpring agree to collaborate on oligonucleotide-peptide conjugates for R&D

Bachem (SIX: BANB) and BioSpring GmbH today announced that the two companies have concluded an...

09. Dec 2011

Bachem expects local sales growth of 6% to 8% in 2011

Today the Bachem Group reduced its expected sales growth rate for the 2011 financial year, from its...

04. Nov 2011

Bachem increases working hours at Swiss sites

Bachem Group (SIX: BANB) today announced that it will increase the work time at its operating sites...

02. Nov 2011

Change in Bachem's Corporate Executive Committee

Bachem Group (SIX: BANB) today announced a change in senior management. Dr. Lester Mills, Chief...

02. Sep 2011

Passing of the Baton at Bachem Group

Bachem Group (SIX: BANB) today announced top-level management changes that will take effect in April...

26. Aug 2011

Bachem Shows Strength and Continues the Upswing

Bachem Group <media 1410 _top>(SIX: BANB)</media> performed well during the first semester of 2011...

09. Aug 2011

Bachem renews supply contract with AstraZeneca

Bachem today announced the renewal of a supply agreement with AstraZeneca, thereby extending the...

29. Jun 2011

Bachem celebrates 40th anniversary

Bachem AG, market leader in peptide-based active pharmaceutical ingredients for the pharma and...

10. Jun 2011

Integration of Sochinaz SA completed at mid-year

The plant in Vionnaz will operate as a branch of Bachem AG with the same line of products and...

11. Mar 2011

Bachem regains the upswing - significantly improved Business Performance in second semester

The Bachem Group gained significant momentum in the second half of 2010 after a slow start to the...

09. Sep 2010

Bachem and Atheris collaborate on Melusine® venom peptide libraries for lead discovery

Bachem today announced that the company concluded an agreement with Atheris Laboratories to market...

20. Aug 2010

Difficult start to first half-year of 2010 for the Bachem Group

Positive sales trend thanks to acquisition of projects and recovery of demand. In the first half of...

17. Jun 2010

Bachem sells stake in Polyphor to Ingro Finanz AG

Bachem today announced that the company on June 16, 2010, has sold its complete stake in Polyphor AG...

02. Jun 2010

Bachem to supply ISA Pharmaceuticals with finished dosage forms immunotherapeutic HPV-SLP for phase III clinical trials

Bachem and ISA Pharmaceuticals B.V. today announced the conclusion of an agreement for the...

19. Mar 2010

Bachem confirms high profitability also in the business year 2009

Bachem today confirms high profitability also in the business year 2009, although North America...

19. Mar 2010

Bachem confirms high profitability also in the business year 2009

Bachem today confirms high profitability also in the business year 2009, although North America...

14. Aug 2009

Bachem Group Half-Year Results 2009

Compared with the first half of 2008, overall sales are down 7.6% in CHF. The EBIT margin is at...

26. May 2009

Stephan Schindler to become new CFO of Bachem Group

Bachem today announced that Stephan Schindler will succeed Michael Hüsler as CFO of the Bachem Group...

23. Apr 2009

Annual General Meeting elects new member of the Board of Directors

Bachem announced today that Dr. Jürgen Brokatzky-Geiger was elected at the Annual General Meeting of...

31. Mar 2009

Bachem and Debiopharm sign follow-up contract for long-term supply of Triptorelin Pamoate

Bachem and Debiopharm today announced the conclusion of a follow-up agreement for the long-term...

13. Mar 2009

Bachem announces financial results for the business year 2008

In the business year 2008, the Bachem Group achieved sales of CHF 195.0 million. Compared with the...

28. Jan 2009

Bionor Immuno and Bachem sign agreement on supply of active ingredients and finished dosage forms for Bionor Immuno's vaccine development projects

Bachem and Bionor Immuno announced today the conclusion of an agreement for the development and...

17. Sep 2008

Bachem enlarges Corporate Executive Committee

Bachem announced today that Dr. Lester Mills will become the fourth member of the company's...

15. Aug 2008

Bachem Group Half-Year Result 2008

Sales of the Bachem Group reached CHF 98.7 million in the first six months of 2008. In local...

10. Apr 2008

Action Pharma and Bachem cooperate on AP214 - now ready to enter Phase 2 clinical trials

Action Pharma A/S and Bachem today announced their cooperation on AP214, Action Pharma's lead...

14. Mar 2008

Record year for Bachem at all levels in 2007

Sales grow to CHF 198.3 Million - up 17.0% in local currencies and 15.5% in CHF...

04. Feb 2008

Bachem production facilities licensed for the manufacture of APIs for the Japanese market

Bachem announced today that the Japanese Ministry of Health, Labour and Welfare has granted the...

17. Aug 2007

New record results for Bachem in the first half of 2007

With an increase in sales of 25.4% in CHF or 26.3% in local currencies compared with the first six...

09. Aug 2007

Bachem Joint Venture Pevion Biotech Secures CHF 35 Million in Series A Financing Round

Bachem today announced that the company has participated in the first substantial private financing...

20. Jun 2007

Bachem renews supply agreement with AstraZeneca

Bachem today announced the renewal of a supply agreement with AstraZeneca. Bachem has supplied...

30. May 2007

Bachem and Intercell agree long-term supply contract for peptide component of vaccine adjuvant IC31

Bachem and Intercell AG today announced the conclusion of a long-term supply agreement for KLK. In...

09. May 2007

Neuren and Bachem continue close collaboration on Glypromate® - Neuren's lead product now in phase III

Bachem and Neuren Pharmaceuticals Limited today announced to continue their close collaboration on...

16. Mar 2007

Bachem reports record results on 2006 sales and profit

The Bachem Group (SWX: BANB) today announced results for the business year 2006. The company...

11. Jan 2007

Bachem and Ardana Sign Long-term Supply Agreement for Aviptadil

Bachem AG and Ardana plc today announced the conclusion of a long-term supply agreement for...

18. Aug 2006

Bachem posts sharp rise in profits in the first half of 2006

- Sales growth of 16.3% in CHF and 14.4% in local currencies  - Operating profit and net profit up...

27. Jul 2006

Bachem Completes Expansion of Peptide Manufacturing Capacities in the US

The Bachem Group (SWX: BANB) announced today that it has opened its new production unit at its US...

07. Apr 2006

Bachem reports record year: highest turnover in the company's history and marked net income growth

- Record sales driven by strong second half and continued dynamic growth of the active ingredients...

29. Mar 2006

Bachem Group with new production unit for cytotoxic substances

The Bachem Group announced today that, at the end of 2005, its subsidiary Sochinaz SA completed the...

16. Mar 2006

Bachem and Debio conclude long-term supply agreement for triptorelin pamoate

Bachem and Debio conclude long-term supply agreement for triptorelin pamoate. Bachem AG today...

09. Mar 2006

Swedish Orphan International and Bachem conclude long-term supply agreement for nitisinone

Bachem AG, Bubendorf, Switzerland and Swedish Orphan International AB, Stockholm, Sweden, today...

27. Jan 2006

Bachem 2005 - Strong second half drives record sales.

The Bachem Group (SWX: BANB) recorded its highest sales ever in 2005, totaling CHF 153.7 million....